Initial Statement of Beneficial Ownership (3)
April 03 2018 - 4:18PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Eddy Jodi Euerle
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/1/2018
|
3. Issuer Name
and
Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [BSX]
|
(Last)
(First)
(Middle)
300 BOSTON SCIENTIFIC WAY
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
SVP and CIO /
|
(Street)
MARLBOROUGH, MA 01752-1234
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock
|
14203.0000
(1)
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Deferred Stock Units
|
(2)
|
1/2/2019
(2)
|
Common Stock
|
2099.0000
(3)
|
(4)
|
D
|
|
Deferred Stock Units
|
(5)
|
2/22/2021
(5)
|
Common Stock
|
5214.0000
(6)
|
(4)
|
D
|
|
Deferred Stock Units
|
(7)
|
2/23/2020
(7)
|
Common Stock
|
2208.0000
(8)
|
(4)
|
D
|
|
Deferred Stock Units
|
(9)
|
2/24/2019
(9)
|
Common Stock
|
230.0000
(10)
|
(4)
|
D
|
|
Deferred Stock Units
|
(11)
|
2/28/2022
(11)
|
Common Stock
|
5703.0000
(12)
|
(4)
|
D
|
|
Stock Option (Right to Buy)
|
(13)
|
2/24/2024
|
Common Stock
|
3000.0000
|
$13.0800
|
D
|
|
Stock Option (Right to Buy)
|
(14)
|
2/23/2025
|
Common Stock
|
16697.0000
|
$16.3100
|
D
|
|
Stock Option (Right to Buy)
|
(15)
|
2/22/2026
|
Common Stock
|
27675.0000
|
$17.2600
|
D
|
|
Stock Option (Right to Buy)
|
(16)
|
2/28/2027
|
Common Stock
|
25252.0000
|
$24.5500
|
D
|
|
Explanation of Responses:
|
(1)
|
Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
|
(2)
|
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on January 2, 2015, the first anniversary of the date of grant.
|
(3)
|
This amount represents the unvested portion of DSUs awarded on January 2, 2014, which will continue to vest in one remaining installment on the anniversary of the date of grant.
|
(4)
|
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
|
(5)
|
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
|
(6)
|
This amount represents the unvested portion of DSUs awarded on February 22, 2016, which will continue to vest in three remaining installments on the anniversary of the date of grant.
|
(7)
|
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
|
(8)
|
This amount represents the unvested portion of DSUs awarded on February 23, 2015, which will continue to vest in two remaining installments on the anniversary of the date of grant.
|
(9)
|
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.
|
(10)
|
This amount represents the unvested portion of DSUs awarded on February 24, 2014, which will continue to vest in one remaining installment on the anniversary of the date of grant.
|
(11)
|
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
|
(12)
|
This amount represents the unvested portion of DSUs awarded on February 28, 2017, which will continue to vest in four remaining installments on the anniversary of the date of grant.
|
(13)
|
Grant to the reporting person of an option to purchase a 3,000 shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.
|
(14)
|
Grant to the reporting person of an option to purchase a 16,697 shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
|
(15)
|
Grant to the reporting person of an option to purchase a 27,675 shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
|
(16)
|
Grant to the reporting person of an option to purchase a 25,252 shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Eddy Jodi Euerle
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA 01752-1234
|
|
|
SVP and CIO
|
|
Signatures
|
/s/ Vance R. Brown, Attorney-in-fact
|
|
4/3/2018
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Apr 2023 to Apr 2024